PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Novikoff, A. ; Müller, T.D.

SURMOUNTing body weight barriers in type 2 diabetes.

Med. 4, 849-851 (2023)
Publ. Version/Full Text DOI PMC
Free by publisher
The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.1.
Altmetric
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Editorial
Keywords Obesity
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 2666-6359
e-ISSN 2666-6340
Journal Med (N Y)
Quellenangaben Volume: 4, Issue: 12, Pages: 849-851 Article Number: , Supplement: ,
Publisher Cell Press
Publishing Place 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-221
G-502200-001
Grants German Center for Diabetes Research (DZD e.V.)
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted
DOI 10.1016/j.medj.2023.11.007
WOS ID 001135524500001
Scopus ID 85178999590
PubMed ID 38070476
Erfassungsdatum 2023-12-11
[➜Report correction]